A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
The purpose of this study is to monitor the long-term safety of participants who received idecabtagene vicleucel treatment as part of the KarMMa-9 (CA089-1043) Phase 3 clinical trial.
Multiple Myeloma
DRUG: Idecabtagene vicleucel
Participant adverse events, Monthly from months 4-18, every 2 months from months 19-59, and annually from month year 5 to 15|Number of participants with positive replication-competent lentivirus test results, At 4, 7, 13, and 25 months, and annually up to 15 years|Persistent vector sequence monitoring, Months 7-18 and annually from years 5-15
Progression-free survival (PFS), Monthly up to 18 months and every two months after month 19 up to 15 years|Overall survival (OS), Every 3 months up to month 60, annually thereafter up to 15 years|Number of participants that achieve complete response or stringent complete response, At months 4-18, every 2 months from months 19-59, and annually from years 5-15|Health-related quality of life (HRQoL) measured by the European Organization for Research and Treatment of Cancer core quality of life (EORTC QLQ-C30) questionnaire, At months 4-18, every 2 months from months 19-59, and annually from years 5-15|Health-related quality of life (HRQoL) measured by the European Organization for Research and Treatment of Cancer assessment of quality of life of myeloma patients (EORTC QLQ-MY20) questionnaire, At months 4-18, every 2 months from months 19-59, and annually from years 5-15|Health-related quality of life (HRQoL) measured by the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire, At months 4-18, every 2 months from months 19-59, and annually from years 5-15
The purpose of this study is to monitor the long-term safety of participants who received idecabtagene vicleucel treatment as part of the KarMMa-9 (CA089-1043) Phase 3 clinical trial.